|
A single study is listed as being challenged. Have others: From 2010 - "In this 36-week study, partial and nonresponders to placebo, and responders and partial responders to Prozac, CBT, and combination treatments in the 12-week trial were openly treated (TADS Team, 2007). As in Phase 1, Prozac and combination groups received additional encouragement and contact (medication management). Despite this, all treatment conditions converged by 30 weeks and remained so by Week 36, with significantly more suicidal ideation in the Prozac-alone group. The percentage of suicidal events for those on Prozac, whether in combined or alone groups, was nearly 12%, double the 6% in the CBT group. Despite the convergence of efficacy and continued risks, TADS is often cited as evidence that combining psychotherapy and medication produce superior results (e.g., NIMH, n.d.)." -- https://www.researchgate.net/profile/Dickson_Adom/post/What_... "Collectively, the findings detailed inA.C. Butler et al. / Clinical Psychology Review 26 (2006) 17–3127 this review suggest that CT is highly effective for adult unipolar depression, adolescent unipolar depression,generalized anxiety disorder, panic disorder with or without agoraphobia, social phobia, PTSD, and childhooddepressive and anxiety disorders. The comparison-weighted grand mean effect size for these disorders when compared to no-treatment, wait list, or placebo controls is 0.95 (SD=0.08). CBT is associated with large improvements in symptoms for bulimia nervosa, and the associated effect sizes (M=1.27, SD=0.11) are significantly larger than those that have been found for pharmacotherapy. CBT also has shown promising results as adjunct to pharmacotherapy in the treatment of schizophrenia." -- https://www.get.gg/docs/Empirical-Status-of-CBT.pdf Prozac yields a risk of side effects, and ceasing use brings a strong risk of relapse. Comparatively CBT offers a lasting solution. |